A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax

被引：1

作者：

Sharpe, Chia ^{[1
]}

Elgamal, Sara ^{[1
]}

Fobare, Sydney ^{[2
]}

Furby, Casie ^{[1
]}

Long, Marissa ^{[1
]}

Bryant, Kinsey ^{[1
]}

Cheney, Carolyn ^{[1
]}

Lerma, James R. ^{[1
]}

Johnstone, Megan E. ^{[1
]}

Orry, Andrew ^{[3
]}

Lam, Polo Chun-Hung ^{[3
]}

Abagyan, Ruben ^{[3
]}

Kysil, Volodymyr ^{[4
]}

Gukasyan, Hovhannes ^{[4
]}

Mitkin, Oleg ^{[4
]}

Karapetian, Ruben ^{[4
]}

Ryakhovskiy, Alexey ^{[4
]}

Bulanova, Elena ^{[4
]}

Parchinsky, Vladislav ^{[4
]}

Ivachtchenko, Alexandre ^{[4
]}

Dokukina, Kate ^{[5
]}

Pushechnikov, Alexei ^{[4
]}

Savchuk, Nikolay ^{[5
]}

Dukes, Iain ^{[5
]}

Burd, Amy ^{[5
]}

Hertlein, Erin K. ^{[1
]}

Byrd, John C. ^{[1
]}

机构：

[1] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA

[2] Ohio State Univ, Med Scientist Training Program, Columbus, OH USA

[3] MolSoft LLC, San Diego, CA USA

[4] ChemDiv Inc, San Diego, CA USA

[5] Eilean Therapeut, Philadelphia, PA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-189266

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] Novel Pi3kd Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies
Sasi, Binu Kandathil Parambil
Tarantelli, Chiara
Civanelli, Elisa
Cannas, Eleonora
Fernandes, Stacey M.
Shupe, Samantha J.
Lahn, Michael
van der Veen, Lars
Di Conza, Giusy
Bertoni, Francesco
Brown, Jennifer R.
BLOOD, 2023, 142
[32] Found in Translation : How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
Leverson, Joel D.
Sampath, Deepak
Souers, Andrew J.
Rosenberg, Saul H.
Fairbrother, Wayne J.
Amiot, Martine
Konopleva, Marina
Letai, Anthony
CANCER DISCOVERY, 2017, 7 (12) : 1376 - 1393
[33] Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations
Lucas, Fabienne
Larkin, Karylin
Gregory, C. Thomas
Orwick, Shelley
Doong, Tzyy-Jye
Lozanski, Arletta
Lozanski, Gerard
Misra, Shrilekha
Ngankeu, Apollinaire
Ozer, Hatice Gulcin
Sampath, Deepa
Thangavadivel, Shanmugapriya
Yilmaz, Selen A.
Rogers, Kerry A.
Byrd, John C.
Woyach, Jennifer A.
Blachly, James S.
BLOOD, 2020, 135 (24) : 2192 - 2195
[34] Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model
Booher, Robert
Dellarocca, Steven
Atoyan, Ruzanna
Borek, Mylissa
Samson, Maria Elena S.
Tuck, David
BLOOD, 2017, 130
[35] Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma
Malarikova, Diana
Jorda, Radek
Dolnikova, Alexandra
Pokorna, Eva
Kazantsev, Dmitry
Havranek, Ondrej
Helman, Karel
Klanova, Magdalena
Strnad, Miroslav
Trneny, Marek
Klener, Pavel, Jr.
BLOOD, 2021, 138
[36] Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety
Lee, Myongjae
Je, In-Gyu
Kim, Jeong Eun
Yoo, Yeongran
Lim, Jong-Ha
Jang, Eunhye
Lee, Yoonsuk
Song, Dong Keun
Moon, An-Na
Kim, Jeong-Ah
Jeong, Jinah
Park, Joon-Tae
Lee, Jung Woo
Yang, Ji-Hoon
Hong, Chang-Hee
Park, Sun-Young
Park, Young-Whan
Baek, Nam Seok
Lee, Sungsook
Ha, Kyoung Soo
Choi, SungKu
Lee, Won Sik
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (03) : 333 - 342
[37] Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia
Luedtke, Daniel A.
Su, Yongwei
Edwards, Holly
Polin, Lisa
Kushner, Juiwanna
Dzinic, Sijana H.
Lin, Hai
Taub, Jeffrey W.
Ge, Yubin
BLOOD, 2018, 132
[38] The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies
Briani, Chiara
Visentin, Andrea
Castellani, Francesca
Cacciavillani, Mario
Trentin, Livio
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (04):
[39] Development of a Convergent Large-Scale Synthesis for Venetoclax, a First-in-Class BCL-2 Selective Inhibitor
Ku, Yi-Yin
Chan, Vincent S.
Christesen, Alan
Grieme, Timothy
Mulhern, Mathew
Pu, Yu-Ming
Wendt, Michael D.
JOURNAL OF ORGANIC CHEMISTRY, 2019, 84 (08): : 4814 - 4829
[40] A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Wierda, William G.
Lee, Seung Tae
Chen, Rong
Zheleva, Daniella
Blake, David
Chiao, Judy H.
Plunkett, William
BLOOD, 2019, 134

← 1 2 3 4 5 →